Saskatchewan Blue Cross launches flexible unparalleled health plan for those 50+
New Retiree Plan offers guaranteed acceptance, comprehensive drug and travel benefits with 36 customizable coverage combinations to reflect the changing retirement landscape.
SASKATOON, SK, June 12, 2025 /CNW/ - As the residents of Saskatchewan retire, many are left navigating a new chapter without the security of health insurance. Rising healthcare costs and changing wellness needs make retiring confidently more complicated than ever.
In response to the need for accessible health plan solutions that can fit any health and financial situation and evolve with you as your needs change with age, Saskatchewan Blue Cross has launched a new Retiree Plan, providing extensive flexible health and travel benefits for individuals 50 and older.
"Retirement isn't a one-size-fits-all journey, and your retirement health plan shouldn't be either," says Kelly Wilson, President and CEO of Saskatchewan Blue Cross. "With unparalleled flexibility our new Retiree Plan adapts seamlessly to diverse health needs and financial situations and removes barriers to access by eliminating health questionnaires that exclude pre-existing conditions from coverage. We're proud to empower retirees with a plan that supports their well-being every step of the way, through innovative services like virtual care, preventative wellness programs, comprehensive coverage and a commitment to providing benefits that support holistic, proactive healthcare."
Why this matters now
With 135,000 Saskatchewan residents approaching retirement in the next five years, the transition from workplace benefits to a strong personal health plan is key. People are living longer, managing complex health needs, and expecting more from their health plan. For rural retirees, access is everything. Our plans come with embedded virtual care, 24/7 navigation and support that meets you where you are.
What makes the Retiree Plan different
Unlike traditional products, Saskatchewan Blue Cross' new plan offers ultimate flexibility, including:
Expanded travel protection – up to 65 days per trip, with $5 million in out-of-province/out-of-country emergency medical coverage.
No medical questionnaires or exclusions for pre-existing conditions – you're covered regardless of your health or prescription medications
36 plan combinations across three tiers (Basic, Classic and Enhanced) – allowing you to match your health and financial needs, with the option to adjust as needed*.
Expansive drug coverage, including vaccines and Exception Drug Status (EDS) medications – plus smoking cessation supports and more.
Robust health practitioner and extended benefits coverage – including annual eye exams, physiotherapy, counselling and more.
Virtual care on demand – providing unlimited access to Nurse Practitioners through Cleveland Clinic Canada, allowing you to address multiple concerns in one visit.
Enhanced mental wellness support – up to 20 counselling sessions with unlimited cases through Homewood Health's Individual Assistance Program (IAP).
Life Smart Coaching and preventative wellness – including Health Risk Assessments, nutrition, financial planning and more.
Optional dental coverage – the ability to tailor coverage and opt out, offering flexibility for those eligible under the Canada Dental Care Plan.
Ongoing plan flexibility – with the option to increase your coverage at any time or decrease after two years*.
Built for Saskatchewan, by Saskatchewan
As a not-for-profit organization trusted by generations, Saskatchewan Blue Cross understands and integrates with provincial health programs, ensuring you get the maximum value from your benefits plan and government plans you're eligible for.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Cision Canada
10 hours ago
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Cision Canada
21 hours ago
- Cision Canada
Jill White Launches "Becoming Her Again," a Coaching Journey for Christian Women Over 40 Rebuilding Purpose and Confidence
The program offers a faith-rooted framework to help women rediscover their identity, confidence, and purpose during and after midlife transitions NEW BRAUNFELS, Texas, June 12, 2025 /CNW/ -- Jill White, Certified Life and Business Coach, international speaker, and founder of Overflow Coaching, is proud to announce the launch of her new signature program, "Becoming Her Again", a 90-day transformational experience created for Christian women over 40 who feel disconnected from their identity and uncertain about what's next. Launching on June 15, 2025, the program is designed to help midlife women navigate the emotional and spiritual impact of life transitions like empty nests, career shifts, divorce or widowhood. With a faith-based, purpose-driven approach, Becoming Her Again blends mindset coaching, identity work, and personal growth strategy to help participants rediscover who they are, renew their purpose, and rebuild confidence from the inside out so they can be successful as they enter their next season of life. According to a recent Barna study, 73% of Christian women over 40 report feeling uncertain about their purpose in this stage of life, despite deep spiritual roots and a history of leadership in their homes, churches, and communities. "This program was born out of conversations with women who kept saying, 'I don't even recognize myself anymore,'" says Jill White. " Becoming Her Again gives them a place to remember who God created them to be and believe it's not too late to step into something beautiful with peace, purpose, and confidence again." Through one-on-one guidance, community support, and biblically aligned tools, Jill helps women break free from identity loss and self-doubt to confidently embrace their next chapter. The coaching process combines almost four decades of experience in coaching and mentoring, education, and leadership with spiritually grounded insights, offering a path for lasting transformation.
